SB17
Samsung Bioepis
['ustekinumab', 'derm']
at the american academy of dermatology ( ) annual meeting, shared positive results from a phase 1 study comparing its ustekinumab #biosimilars (sb17) with the reference product (stealara). #aad2023 
Your Resource for Emerging Therapies.